Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Palatin Technologies and King Pharmaceuticals have revealed positive results from the second part of a phase IIa study evaluating the effects of bremelanotide in post-menopausal women diagnosed with female sexual arousal disorder.
Subscribe to our email newsletter
Results showed that on a 14-item questionnaire, 73% of the women reported an increased level of genital arousal while on bremelanotide, compared with 23% of women on placebo.
In addition, 46% of women on bremelanotide reported an increased level of sexual desire, while only 19% of women responded similarly after placebo treatment. Subjects receiving bremelanotide also reported a higher incidence of engaging in sexual activity compared to placebo.
The current study follows a similarly designed clinical study conducted with pre-menopausal patients with female sexual arousal disorder (FSAD).
“The results of this study in post-menopausal women corroborate the previous results reported in pre-menopausal women and supports the further advancement of bremelanotide for the treatment of FSAD,” said Dr Trevor Hallam, executive vice president of R&D at Palatin.
The companies are currently enrolling subjects in a 100- patient, phase IIb at-home clinical trial in pre-menopausal FSAD patients at approximately 20 clinical sites throughout the US.